Hester Biosciences Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Fiscal Year 2019
August 13, 2018 at 10:57 am IST
Share
Hester Biosciences Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2018. The company net sales have gone up by 32% as compared to the equivalent first quarter of last to last year the company recorded sales of INR 382.6 million as against INR 290.4 million. The reason for this topline growth is mainly attributed to the expanded capacity and also shifting the company focuses on high value products. Talking about the net profit the profit of the company has improved the company's EBITDA as well as the net profit and the attributes for this are again that the company has improved the company's cost of goods sold there has been higher efficiencies in the company's production that have been incorporated as well as better inventory management. Net profit is achieved at 25.31% of total sales for first quarter of fiscal year 2019 as against 21.18% of sales in first quarter of fiscal year 2018. The company has invested INR 13.2 million in capex during the first quarter of fiscal year 2019 as against INR 43.0 million in first quarter of fiscal year 2018. ROE stands at 24.87% as against 19.55% for the quarter. Non-annualized EPS for first quarter fiscal year 2019 is at INR 11.38 per share as against INR 7.23 per share in first quarter of fiscal year 2018. Consolidated debts are INR 517.4 million in the fiscal first quarter of 2019 as against INR 600.2 million for fiscal year 2018. Total Revenue was INR 390.33 million compared to INR 295.94 million a year ago. Profit before tax was INR 134.04 million compared to INR 94.41 million a year ago. Profit for the period was INR 96.84 million compared to INR 61.76 million a year ago.
For the current fiscal year 2019, the company expects to maintain a growth in sales at least what the company has shown and on the profit side the minimum that the company will have is what the company has registered in this quarter.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
Hester Biosciences Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Fiscal Year 2019